GlassScriptPhysician profile
Nina Wilson
NPI 1215491717
$759.63
in general payments reported to CMS, 2019-2025
20 companies · $14.41 in 2025
The $14.41 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $80.85 · 2023: $318 · 2024: $347 · 2025: $14.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $658 · Consulting Fee: $20.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $658.38 |
| Consulting Fee | $20.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $186.66 | 2022-2024 | Tezspire, Fasenra |
| Takeda Pharmaceuticals U.S.A., INC. | $96.01 | 2023-2024 | Hyqvia, Cuvitru |
| Tersera Therapeutics LLC | $52.40 | 2022-2023 | Quzyttir |
| Eisai INC. | $42.58 | 2023-2024 | |
| Novo Nordisk INC | $40.00 | 2023 | |
| Genzyme Corporation | $34.31 | 2024 | |
| Hospira, INC. | $33.07 | 2024-2025 | |
| Ucb, INC. | $32.65 | 2024 | Rystiggo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.08 | 2023 | Spevigo |
| Pfizer INC. | $27.57 | 2023 | |
| Alnylam Pharmaceuticals INC. | $24.26 | 2022 | |
| Alexion Pharmaceuticals, INC. | $22.85 | 2024 | Ultomiris |
| Adma Biomanufacturing LLC | $20.40 | 2024 | |
| Organon LLC | $20.28 | 2023 | Renflexis |
| Lilly USA, LLC | $19.38 | 2024 | Omvoh |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $18.74 | 2024 | |
| Argenx US, INC. | $18.02 | 2024 | Vyvgart Hytrulo, Vyvgart |
| Glaxosmithkline, LLC. | $15.81 | 2024 | Nucala |
| Tg Therapeutics, INC. | $13.45 | 2024 | |
| Amgen INC. | $13.11 | 2024 | Evenity, Prolia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nina Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.